Curacle Signs a License and Collaboration Agreement with Théa for Development and Commercialization of CU06-RE to treat Diabetic Macular Edema and Wet-AMD

October 28, 2021 Auto Bot Diabetic Macular Edema, Pharma, wet AMD 0

Shots:

  • Curacle to receive a total of ~$2B including $6M up front & is eligible to receive ~$157.5M as development, regulatory and sales milestones along with royalties on sales upon the successful development of CU06-RE. The companies will closely collaborate on the clinical development of the product
  • Curacle will hold the marketing rights in all Asia countries & will lead the P-I & II clinical studies with TOI to provide both financial and infrastructure support while Théa will get the marketing rights in all other countries globally
  • The focus of the collaboration is to provide a new treatment with an alternative and non-invasive RoA for patients

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Businesswire

The post Curacle Signs a License and Collaboration Agreement with Théa for Development and Commercialization of CU06-RE to treat Diabetic Macular Edema and Wet-AMD first appeared on PharmaShots.